HTR1A and prostate cancer: The cytotoxic activity of S14506 against prostate cancer PC-3 cells (but not against neuroblastoma SH-SY5Y cells, Figure 8 and Figure 9) was reversed by treatment with the 5-HT1A receptor antagonist WAY100635 and inverse agonist spiperone.